Accordingly, increasing evidence demonstrates that TIMP-1 is overexpressed in several types of human cancers, including lung cancer [18,19], colon cancer [20], prostate cancer [21], melanoma [22], glioblastoma [23] and breast cancer [24,25], and its increased expression is correlated with a poor prognosis of the patient. Here, TIMP1 is linked to breast cancer.